Tetrahydrocannabivarin

Tetrahydrocannabivarin (THCV): A Comprehensive Reference

1. Identity, Chemical Structure, and Natural Sources

Chemical and Botanical Names

Tetrahydrocannabivarin (THCV), formally designated Δ9-tetrahydrocannabivarin (Δ9-THCV), carries the systematic names (−)-trans-Δ9-tetrahydrocannabivarin and (6aR,10aR)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol. It is also known by the identifiers O-4394 and GWP42004 in research and patent literature. THCV is a homologue of tetrahydrocannabinol (THC) having a propyl (3-carbon) side chain instead of a pentyl (5-carbon) side chain, making it non-psychoactive in lower doses. THCV is the propyl analog of THC in which the five-carbon side chain is shortened by two methylene units.

Tetrahydrocannabivarins (THCVs) are not tetrahydrocannabinols (THCs) nor are they THC isomers. There is no known biosynthesis pathway in the cannabis plant, nor any synthetic chemical reaction, that can convert THC to THCV or vice versa. The length of the alkyl chain is the main structural difference between these two precursors, which leads to THCV having a smaller molecular weight than THC.

Botanical Source

The plant Cannabis sativa contains over 400 chemical compounds, including about 80 terpeno-phenols unique to the plant, known as phytocannabinoids. THCV is one such minor phytocannabinoid. THCV is defined as a propyl analogue of THC, commonly found in low concentrations in dried cannabis plant material, but can be present in higher amounts in specific THCV-rich strains.

THCV is commonly present, especially in landraces from South Asia and Africa. Tetrahydrocannabivarin (THCV) and cannabidivarin (CBDV) are short-tailed C19 analogs of THC and CBD. THCV appears as a fractional component of many southern African cannabis chemotypes, although plants highly predominant in this agent have been produced. A study published in the American Journal of Botany in 2004 tested landrace populations from across the world to determine their cannabinoid content and ratios. THCV was found to be present in all varieties, with higher concentrations in feral C. indica populations originating in Central/Southeast Asia and Southern Africa.

Biosynthesis

In the cannabis plant, THCV's biosynthetic pathway leads to the formation of cannabigerovarinic acid (CBGVA), which then reacts with an enzyme called THCV synthase to form tetrahydrocannabivarin carboxylic acid (THCVA). THCVA is then broken down into THCV via the same decarboxylation process that THCA undergoes to produce THC. In the cannabis plant, tetrahydrocannabivaric acid (THCVA) originates from varinolic acid, in contrast to olivetolic acid, which is the origin of tetrahydrocannabinolic acid (THCA). After biosynthesis, natural decarboxylation, which can be accelerated with heat, converts the acidic precursors THCVA and THCA to neutral THCV and THC, respectively.

Natural Distribution and Commercial Forms

THCV is prevalent in certain central Asian and southern African strains of Cannabis. Notable THCV-containing landrace varieties include South African strains such as Durban Poison. Durban Poison is known for its sweet, fruity flavour, high Δ9-THC level ranging from 15–25%, low CBD level (0.1–0.3%), and CBG (0.6–1.4%) and THCV (0.2–1.8%).

THCV is available commercially in several forms, including isolated or concentrated THCV oils, oral capsules, sublingual tinctures, mucoadhesive oral strips, and full-spectrum cannabis preparations. Pharmaceutical-grade botanical drug substances (BDS) derived from cannabis with a THCV content of greater than 70% of total cannabinoids have been described in patent literature, obtained by extraction with carbon dioxide followed by secondary extraction to remove non-cannabinoid materials including waxes, terpenes, and flavonoids. THCV also exists in a Δ8-isomeric form (Δ8-THCV), which has been used in some clinical pharmacology studies.

2. Traditional and Historical Use

Cannabis in Africa and Asia

THCV itself was not identified as a discrete chemical entity until the 20th century, and traditional cultures using cannabis were not aware of its constituent phytocannabinoids as distinct molecules. Nonetheless, the cannabis plant preparations used historically in regions where THCV-rich strains predominate are documented.

About 1,000 years ago, cannabis first entered Africa from its homeland in Southern Asia. It was (and remains) valued in African culture and smoked in pipes, a practice invented in Africa, according to the Oxford Research Encyclopedia. THCV was studied by Roger Adams as early as 1942. Its pharmacological properties have been studied since the early 1970s, when it was recognized that it behaves as a significantly weaker agonist (approximately fivefold) compared to THC.

Early human pharmacological data appeared in 1974: In a 1974 human study investigating structure-activity relationships of cannabis constituents, 7 mg of THCV felt similar to THC, with an estimated potency of approximately 25% that of THC.

African landraces growing closer to the Equator may display higher concentrations of tetrahydrocannabivarin (THCV), which may be one reason why so many African varieties are known for their uplifting, energetic effects. The indigenous communities of Southern Africa (including the Khoikhoi, San, and Bantu tribes) used these native, THCV-enriched sativa-type cannabis strains traditionally, primarily via smoking and in pipe preparations, for ceremonial and medicinal purposes—though documentation of the specific role THCV played pharmacologically is absent from historical records, as phytocannabinoid profiling did not exist as a discipline at that time.

3. Key Constituents, Chemical Form, and Mechanisms of Action

Primary Compound

The primary bioactive compound is Δ9-tetrahydrocannabivarin itself. In the intact plant, it exists largely as the inactive acidic precursor THCVA; heat-mediated decarboxylation converts it to the active neutral form THCV. In the plant, THCV is an inactive molecule in the carboxylic acid form that can be decarboxylated and activated when heated, dried, or exposed to light.

Cannabinoid Receptor Activity (CB1 and CB2)

THCV is a cannabinoid receptor type 1 (CB1) antagonist or, at higher doses, a CB1 receptor agonist, and a cannabinoid receptor type 2 (CB2) partial agonist. THCV stands out among cannabinoids due to its dual mechanism of action as an antagonist on CB1 and a partial agonist on CB2. This dual and dose-dependent profile distinguishes it clearly from Δ9-THC, which acts as a CB1 agonist across most dose ranges.

Evidence from competitive binding and GTPγS-binding experiments with mouse brain and CHO-hCB2 cell membranes demonstrates that THCV is a competitive cannabinoid CB1 and CB2 receptor antagonist. THCV antagonized THC in the mouse isolated vas deferens, in a manner suggesting competition with THC for CB1 receptors.

Both THC and THCV display complex pharmacology, including partial agonist and dose-dependent effects at CB1 receptors, as well as activity at CB2 and non-cannabinoid targets. THCV's unique pharmacological profile is characterized by partial agonism, dose-dependent substitution for THC, and antagonism at higher doses.

Non-Cannabinoid Receptor Targets

Evidence has been presented that THCV shares the ability of CBD to enhance 8-OH-DPAT-induced activation of 5-HT1A receptors in vitro, and produces apparent antipsychotic effects in rat models of schizophrenia-like symptoms that are, at least in part, 5-HT1A receptor-mediated.

Studies have indicated that THCV's effects may involve signaling through GPR55, as shown in experiments comparing GPR55 knockout and wild-type mice. These findings suggest that GPR55-mediated mechanisms may partially account for THCV's ability to regulate glucose tolerance and energy balance.

THCV has recently attracted attention due to its structural similarity to THC and its potential therapeutic properties. Preliminary studies suggest that THCV may interact with the endocannabinoid and vanilloid systems in distinct ways, possibly exerting unique effects on nociception, inflammation, and neuroprotection. In particular, interactions with TRP (transient receptor potential) channels, including TRPV2, have been proposed as contributing to anti-inflammatory and analgesic effects.

Metabolic Signaling

Nuclear magnetic resonance (NMR)-based metabolomics studies have confirmed that THCV induced post-translational modifications in CREB, AMPKα2, PRAS40, and STAT proteins in hepatocytes, suggesting an enhanced ability to metabolize lipids and an increase in mitochondrial activity essential for energy expenditure.

4. Scientific Evidence by Area of Use

4.1 Metabolic Disorders: Obesity and Appetite Suppression

Preclinical Evidence

In rodent studies, THCV decreases appetite, increases satiety, and up-regulates energy metabolism, making it a candidate remedy for weight loss and management of obesity and type 2 diabetic patients. THCV produces weight loss and decreases body fat and serum leptin concentrations with increased energy expenditure in obese mice.

THCV did not significantly affect food intake or body weight gain in some studies, but produced an early and transient increase in energy expenditure. It dose-dependently reduced glucose intolerance in ob/ob mice and improved glucose tolerance and increased insulin sensitivity in DIO mice, without consistently affecting plasma lipids. THCV also restored insulin signalling in insulin-resistant hepatocytes and myotubes.

In vivo studies that used zebrafish and obese mice further demonstrated that THCV enhances yolk lipid utilization and prevents hepatosteatosis. These findings suggest that THCV may contribute to weight management by improving lipid metabolism and preventing fat accumulation, thus addressing key factors in obesity-related metabolic disorders.

Human/Clinical Evidence

The most significant human clinical trial to date is the Jadoon et al. (2016) pilot study. In this randomized, double-blind, placebo-controlled study, 62 subjects with noninsulin-treated type 2 diabetes were randomized to five treatment arms: CBD (100 mg twice daily), THCV (5 mg twice daily), a 1:1 ratio of CBD and THCV (5 mg/5 mg, twice daily), a 20:1 ratio of CBD and THCV (100 mg/5 mg, twice daily), or matched placebo for 13 weeks.

Compared with placebo, THCV significantly decreased fasting plasma glucose (estimated treatment difference [ETD] = −1.2 mmol/L; P < 0.05) and improved pancreatic β-cell function (HOMA2 β-cell function [ETD = −44.51 points; P < 0.01]), adiponectin (ETD = −5.9 × 10⁶ pg/mL; P < 0.01), and apolipoprotein A (ETD = −6.02 μmol/L; P < 0.05), although plasma HDL was unaffected. CBD and THCV were well tolerated. The study concluded that THCV could represent a new therapeutic agent in glycemic control in subjects with type 2 diabetes.

A more recent human trial used mucoadhesive oral strips: A placebo-controlled study was conducted on 44 subjects (31 females and 13 males) with an average age of 51.75 years. The study evaluated the efficacy of two different doses of THCV and CBD (8 mg THCV/10 mg CBD in the lower dose and 16 mg THCV/20 mg CBD in the higher dose), taken once daily for 90 days. The resulting data revealed clinically significant weight loss and decreases in abdominal girth, systolic blood pressure, and total and LDL cholesterol.

Evidence strength: Preliminary human trials support these findings, showing that THCV may modulate appetite and glycemic control, though larger-scale studies are necessary to confirm its clinical efficacy and safety. The Jadoon et al. study is widely recognized as the most rigorously designed human trial, but it was a pilot study with a small sample size, and results have not yet been independently replicated in larger, longer-duration trials.

4.2 Type 2 Diabetes and Glycemic Control

The mechanisms by which THCV exerts glycemic effects are rooted in its endocannabinoid receptor pharmacology. By improving the efficiency of insulin action, THCV addresses one of the central mechanisms that contributes to hyperglycemia and disease progression. In dietary-induced obesity (DIO) mice, THCV increased the amount of energy used and reduced glucose intolerance in a dose-dependent manner. In addition, THCV enhanced tolerance to glucose and sensitivity to insulin among genetically obese (ob/ob) mice, thereby restoring insulin signaling in hepatocytes and myotubes resistant to insulin.

In the Jadoon et al. clinical trial, THCV on dyslipidemia and glycemic control in type 2 diabetics showed reduced fasting plasma glucose concentration when compared to a placebo group. The study authors concluded that THCV could represent a new therapeutic agent in glycemic control in subjects with type 2 diabetes.

Evidence strength: Preclinical data are robust across multiple animal model systems. Human evidence is promising but currently limited to small pilot trials. No phase III randomized controlled trials have been completed.

4.3 Neuroprotection and Parkinson's Disease

Previous findings have indicated that a cannabinoid such as Δ9-THCV, which has antioxidant properties and the ability to activate CB2 receptors but to block CB1 receptors, might be a promising therapy for alleviating symptoms and delaying neurodegeneration in Parkinson's disease (PD).

Acute administration of Δ9-THCV attenuated the motor inhibition caused by 6-hydroxydopamine, presumably through changes in glutamatergic transmission. Moreover, chronic administration of Δ9-THCV attenuated the loss of tyrosine hydroxylase-positive neurons caused by 6-hydroxydopamine in the substantia nigra, through an effect related to its antioxidant properties.

The antioxidant and CB2 receptor agonist properties of Δ9-THCV afforded neuroprotection in experimental Parkinson's disease (PD), whereas its CB1 receptor antagonist profile at doses lower than 5 mg/kg caused anti-hypokinetic effects. The anti-dyskinetic potential of Δ9-THCV was investigated at a dose of 2 mg/kg administered intraperitoneally for two weeks.

Tetrahydrocannabivarin (range 0.025–2.5 mg/kg) showed promise in models of seizure and hypomobility, Huntington's and Parkinson's disease in a systematic review of minor phytocannabinoids.

Evidence strength: All neuroprotective evidence for THCV in Parkinson's disease is preclinical (rodent models). No human trials in Parkinson's disease or other neurodegenerative conditions have been reported as of the available literature.

4.4 Anticonvulsant and Epilepsy-Related Activity

THCV demonstrates prominent anticonvulsant properties in rodent cerebellum and pyriform cortex. Preclinical studies have demonstrated that tetrahydrocannabivarin (THCV) exhibits antiepileptiform and anticonvulsant properties in vitro and in vivo, suppressing epileptiform activity in rat hippocampal slices and reducing pentylenetetrazol-induced seizures in mice via CB1 receptor-mediated mechanisms. These effects suggest potential utility in epilepsy management, though human translation remains unconfirmed.

Evidence strength: Preclinical only. No controlled human trials specifically investigating THCV as an anticonvulsant agent have been published.

4.5 Antipsychotic and Psychiatric Effects

Studies have aimed to address whether Δ9-THCV can enhance activation of 5-HT1A receptors in vitro and induce any apparent 5-HT1A receptor-mediated antipsychotic effects in vivo. The preclinical results indicate that THCV produces antipsychotic-like effects in rat models through 5-HT1A receptor activation, a mechanism shared with some atypical antipsychotic drugs.

In addition, a randomized, double-blind, placebo-controlled crossover study investigated THCV's interaction with THC-induced psychoactive effects in humans: In that study, 10 male cannabis users were administered THCV (5 mg) or identical placebo capsules before administration of intravenous THC (1 mg). They could not distinguish THCV from placebo, and still reported THC effects after THCV pretreatment. However, THCV pretreatment protected against THC-induced impairments in a verbal recall test.

Evidence strength: Preclinical for primary antipsychotic applications. There is one small human crossover study demonstrating THCV's ability to partially mitigate select cognitive effects of THC. No large-scale human trials for THCV as a primary psychiatric intervention exist.

4.6 Inflammation and Pain

THCV may interact with the endocannabinoid and vanilloid systems in distinct ways, possibly exerting unique effects on nociception and inflammation. Animal model evidence (2010) showed that THCV decreased pain behaviors in a mouse model of pain and inflammation, probably via CB1, CB2, and cyclic AMP production pathways.

THCV displays neuroprotective effects in preclinical paradigms involving oxidative stress and inflammation in dopaminergic neurons. Combined with cannabidiol, THCV also protects against paclitaxel-induced peripheral neuropathy in mice by improving mitochondrial function.

Evidence strength: Preclinical only. No controlled human trials focused on THCV's anti-inflammatory or analgesic efficacy have been completed.

4.7 Cognitive Effects and Attention

A two-phase, dose-ranging, placebo-controlled trial that evaluated the safety and acute effects of THCV in healthy participants revealed that THCV exhibited a favorable safety profile, with most adverse events being mild; lower doses produced a preliminary signal for improved sustained attention, while higher doses resulted in mild THC-like effects.

Evidence strength: Very preliminary. The above represents a single small dose-ranging safety study. Any claims about cognitive enhancement are not supported by efficacy trial data.

5. Body Systems and Health Areas

• Endocannabinoid System: THCV, although structurally similar to THC, has distinct pharmacological activity and physiological effects at the doses currently reported in the literature, acting primarily via dose-dependent modulation of CB1 and CB2 receptors.
• Metabolic / Endocrine System: Effects on insulin sensitivity, fasting plasma glucose, β-cell function, adiponectin levels, lipid metabolism, and energy expenditure, supported by both animal and preliminary human data.
• Central Nervous System (Neurological): Neuroprotective activity in dopaminergic neurons, anticonvulsant activity, anti-hypokinetic effects in Parkinson's models; all preclinical.
• Neuropsychiatric / Serotonergic System: Modulation of 5-HT1A receptors underpins putative antipsychotic activity observed in preclinical models.
• Immune / Inflammatory System: Anti-inflammatory activity via CB2 partial agonism and TRP channel interactions; preclinical only.
• Gastrointestinal / Appetite Regulation: THCV has been reported to reduce blood sugar and act as an appetite suppressant in several independent pre-clinical studies.

6. Dosage Forms and Doses Reported in Studies

The following dosages are reported only as described in the sourced literature; they are not recommendations.

• Type 2 Diabetes Pilot Trial (Jadoon et al., 2016, Diabetes Care): THCV was administered at 5 mg twice daily for 13 weeks in a randomized, double-blind, placebo-controlled study of 62 subjects with noninsulin-treated type 2 diabetes.
• Mucoadhesive Strip Study (2025): The study evaluated the efficacy of two different doses of THCV and CBD (8 mg THCV/10 mg CBD in the lower dose and 16 mg THCV/20 mg CBD in the higher dose), taken once daily for 90 days.
• Dose-Ranging Safety Study (Peters et al., 2023, oral Δ8-THCV): This was a two-phase, dose-ranging, placebo-controlled trial of the Δ8 isomer of oral THCV in healthy adults. Phase 1 utilized an unblinded, single-ascending dose design (n=3). Phase 2 used a double-blind, randomized, within-participant crossover design (n=18). Participants received single acute doses of placebo and 12.5, 25, 50, 100, and 200 mg of THCV.
• THC Attenuation Study (human, small crossover): In a randomized, double-blind, placebo-controlled study, 10 male cannabis users were administered THCV (5 mg) or identical placebo capsules before administration of intravenous THC (1 mg).
• Parkinson's Disease Animal Models: Δ9-THCV was administered intraperitoneally at 2 mg/kg for two weeks in the anti-dyskinesia investigation in Pitx3ak mutant mice.
• Obesity Mouse Models (Nature/Nutrition & Diabetes, 2013): Improvement of liver triglyceride levels was observed with oral THCV at 12.5 mg/kg in ob/ob mice.
• Systematic Review Range (minor phytocannabinoids): Tetrahydrocannabivarin was used at a range of 0.025–2.5 mg/kg in preclinical models of seizure and neurodegeneration.

7. Safety Considerations and Interactions

Psychoactivity and Subjective Effects

Early human studies indicate that low oral doses (10 mg) of Δ9-THC elicit an intoxicating effect, whereas similar doses of Δ9-THCV do not. Only at much higher oral doses of Δ8-THCV (100 and 200 mg) have any cannabis-like effects been documented, though at a considerably lower magnitude than with low doses of Δ9-THC. THCV is generally considered non-psychoactive at low to moderate doses and cannot be discriminated from placebo in healthy humans. However, a recent placebo-controlled study found that THCV produced mild THC-like subjective effects, such as feeling and liking the drug, at higher oral doses (100–200 mg).

Adverse Events in Human Studies

In the dose-ranging safety trial of oral Δ8-THCV, most adverse events (55/60) were mild. Euphoric mood was the most common adverse event. In the Jadoon et al. type 2 diabetes trial, CBD and THCV were well tolerated. A two-phase, dose-ranging, placebo-controlled trial revealed that THCV exhibited a favorable safety profile overall, with most adverse events being mild.

Long-Term Safety

The long-term safety of THCV remains unclear due to the lack of extended clinical studies. While preclinical studies have shown no significant adverse effects, the safety profile of chronic THCV administration in humans must be rigorously evaluated.

Bioavailability and Pharmacokinetic Considerations

One of the significant challenges in THCV-based therapies is poor bioavailability. THCV has a low water solubility, which limits its absorption and systemic availability when orally administered. To address this, innovative drug delivery platforms such as nanoformulations, lipid-based carriers, and emulsified preparations are being explored to improve THCV's pharmacokinetics and therapeutic efficacy.

A human pharmacokinetics study of oral Δ8-THCV found that plasma samples collected from 15 participants after oral Δ8-THCV administration showed detection of the parent compound, its primary metabolites 11-OH-Δ8-THCV and Δ8-THCV-COOH, and isomeric conversion products. Δ9-THCV and Δ8-THC-COOH were present only after the 100 mg and 200 mg doses.

Potential Drug Interactions via CYP450 Enzymes

Despite increasing presence in commercially available products, relatively little research has focused on the impact of "minor" cannabinoids including THCV. In vitro screening showed that THCV and THCVA inhibited or partially inhibited CYP2C19. It is not clear from these in vitro studies whether minor cannabinoids inhibit the CYP450 system in a clinically meaningful way. Given the growing popularity and the increasing number of novel products containing considerable amounts of these constituents, additional research is needed to determine the likelihood of drug-drug interactions related to minor cannabinoids.

The broader context of cannabinoid CYP interactions is relevant: Understanding cannabis-drug interactions is critical given regulatory changes that have increased access to and use of cannabis. Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (Δ9-THC), the most abundant phytocannabinoids, are in vitro reversible and time-dependent (CBD only) inhibitors of several cytochrome P450 (CYP) enzymes. Whether THCV's in vitro CYP inhibition translates to clinically relevant drug interactions in vivo remains formally unstudied.

THCV vs. THC Pharmacology: Regulatory Context

THCV is usually and incorrectly categorized as an intoxicating analogue of tetrahydrocannabinol (THC), which causes confusion among both consumers and regulators. In contrast to THC, clinical and therapeutic advantages of THCV regarding its lack of psychoactive effects in human studies are of great value in pharmacotherapy. On the other hand, the dual pharmacological activities of THCV on CB1/CB2 receptors, exhibiting agonistic and antagonistic effects depending on the dosage, indicate the need for further research.

The dose-dependency of CB1 agonism vs. antagonism is clinically important: Results suggest that THCV may act as a dose-dependent modulator of cannabinoid receptor activity, capable of both mimicking and opposing THC's discriminative stimulus effects. This pharmacological complexity requires that any therapeutic application be carefully calibrated around dose.

References

• Haghdoost M, Peters EN, Roberts M, Bonn-Miller MO. "Tetrahydrocannabivarin is Not Tetrahydrocannabinol." Cannabis Cannabinoid Res, 2025. PMC11947634.
• PMC. "The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management." PMC12011981, 2025.
• Abioye A, et al. "Δ9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes." J Cannabis Res, 2020. PMC7819335.
• PMC. "Weight Loss and Therapeutic Metabolic Effects of Tetrahydrocannabivarin (THCV)-Infused Mucoadhesive Strips." PMC11831893, 2025.
• Jadoon KA, et al. "Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes." Diabetes Care, 2016;39(10):1777–1786.
• Wargent ET, et al. "The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity." Nutrition & Diabetes, 2013.
• Thomas A, et al. "Evidence that the plant cannabinoid Δ9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist." British Journal of Pharmacology, 2005. PMC1751228.
• García C, et al. "Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ9-THCV in animal models of Parkinson's disease." British Journal of Pharmacology, 2011. PMC3165958.
• Espadas I, et al. "Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease." Neurobiology of Disease, 2020. PubMed 32387338.
• Cascio MG, et al. "The phytocannabinoid, Δ9-tetrahydrocannabivarin, can act through 5-HT1A receptors to produce antipsychotic effects." British Journal of Pharmacology, 2015. PMC4337703.
• Bhunia S, et al. "A systematic review of minor phytocannabinoids with promising neuroprotective potential." British Journal of Pharmacology, 2020. PMC7484504.
• Peters EN, et al. "A Two-Phase, Dose-Ranging, Placebo-Controlled Study of the Safety and Preliminary Test of Acute Effects of Oral Δ8-Tetrahydrocannabivarin in Healthy Participants." Cannabis Cannabinoid Res, 2023.
• PMC. "Pharmacokinetics of Oral Cannabinoid Δ8-Tetrahydrocannabivarin and Its Main Metabolites in Healthy Participants." PMC11676667.
• PMC. "Tetrahydrocannabivarin (THCV) Protects Adipose-Derived Mesenchymal Stem Cells (ASC) against Endoplasmic Reticulum Stress Development and Reduces Inflammation during Adipogenesis." PMC10138341, 2023.
• PMC. "Contemplating cannabis? The complex relationship between cannabinoids and hepatic metabolism resulting in the potential for drug-drug interactions." PMC9871609.
• MDPI Biomolecules. "Tetrahydrocannabivarin (THCV) Dose Dependently Blocks or Substitutes for Tetrahydrocannabinol (THC) in a Drug Discrimination Task in Rats." 2025.
• ScienceDirect Topics. "Tetrahydrocannabivarin — Overview." Advances in Pharmacology, 2017.
• PMC. "Finally Freed—Cannabis in South Africa: A Review Contextualised within Global History, Diversity, and Chemical Profiles." PMC11478489.
• PMC. "A classification of endangered high-THC cannabis (Cannabis sativa subsp. indica) domesticates and their wild relatives." PMC7148385.
• DrugBank. "Tetrahydrocannabivarin: Uses, Interactions, Mechanism of Action." DB11755.